OxiMax® N-595 Pulse Oximeter

Products	OxiMax® N-595 Pulse Oximeter
Company	Nellcor
Item	OxiMax® N-595 Pulse Oximeter
Features	Highly Advanced Motion-Tolerant Technology OxiMax Sensor-Monitor Communication Simple, intuitive operation and easy-to-see display. Compatible with the complete family of OxiMax Pulse Oximetry Sensors. Ideal for any clinical environmentmonitors neonates through adults. Convenient selection of adult or neonate alarm limits, and user-configurable power-on settings. Works with the Oxinet® III Central Station and Paging System to provide an easy-to-use, cost-effective monitoring solution for the General Care Floor. Compatible with Nellcor's Score® Analysis Software for overnight oximetry studies. User-selectable fast-averaging mode (2-3 seconds) to more precisely track rapidly changing saturations. On-screen viewing of 48 hours of SpO₂ and pulse rate trends taken at 4-second intervals; printing capability. Variable pitch beep tone enables clinicians to hear changes in SpO₂. Interfaces with certain multiparameter monitors; real-time patient information and true physiologic waveforms are displayed on host system.
Description	As the cornerstone of the revolutionary OxiMax® Pulse Oximetry System, the OxiMax N-595 Pulse Oximeter combines Nellcor's best-in-class pulse oximetry with the versatile OxiMax monitoring platform. The motion-tolerant OxiMax N-595 Pulse Oximeter is equipped with Nellcor's most advanced signal processing technology, which enables it to withstand the most challenging monitoring conditions with substantially greater accuracy than conventional pulse oximetry. The N-595 Pulse Oximeter also includes SatSeconds™ Alarm Management technology, an innovative feature for managing nuisance alarms without sacrificing patient safety.
Info	Nellcor Customer Service: (800) 635-5267 Web site: http://www.nellcor.com/

TAG: OxiMax reg Pulse Oximeter

...ARUP Laboratories is a national reference laborato... research and development. ARUP offers an extensiv...ests in clinical and anatomic pathology. Owned by ... include more than half of the nation's university...

Medicine Products:

Trichloraethanol (Chloral Hydrate Metabolite)Treponema pallidum (Rapid Plasma Reagin) with Reflex to Titer & TP-PA Confirmation Treponema pallidum Antibody by TP-PA (MHA-TP)Trench Fever, IgM

(Date:11/21/2008)...l/ -- Heska Corporation,(Nasdaq: HSKA ) today a...f,Security Analysts, 12th Annual Biotech and Spec...77 Avenue of the Americas, 2nd Floor in New York, ...5 a.m. Eastern Time (7:35 a.m.,Mountain Time) and...eks,following the presentation through a link und...

(Date:11/21/2008)... Lennox-Gastaut syndrome , , FRIDAY, Nov...(rufinamide) has been approved as a supplementary ...nox-Gastaut syndrome, the U.S. Food and Drug Admin...based on results of a four-month clinical trial th...ients who took a placebo, those who took the drug ...

(Date:11/21/2008)...Center.com, the premier site,for online nursing c... been,updated to improve the interactive experien...ippincott Williams & Wilkins (LWW), NursingCen...nuing education activities and free,access to 11,...rnals.,Lippincott Williams & Wilkins is a par...

(Date:11/21/2008)...stCall/ -- Today, prescription drugs are the first...rcent of patients suffering chronic conditions. T...ondition account for 96 percent of all prescriptio...s. A proprietary new pharmacy model developed ove...E: MHS ) significantly reduces critical gaps in ...

Breaking Medicine News(10 mins):Health News:FDA Approves New Drug for Severe Epilepsy 2 Health News:NursingCenter.com Launches New Features to Improve User Experience 2 Health News:NursingCenter.com Launches New Features to Improve User Experience 3 Health News:New Data: Advanced Pharmacy Model Significantly Reduces Gaps in Care for Patients with Chronic and Complex Conditions; Improves Clinical and Financial Outcomes 2 Health News:New Data: Advanced Pharmacy Model Significantly Reduces Gaps in Care for Patients with Chronic and Complex Conditions; Improves Clinical and Financial Outcomes 3 Health News:New Data: Advanced Pharmacy Model Significantly Reduces Gaps in Care for Patients with Chronic and Complex Conditions; Improves Clinical and Financial Outcomes 4 Health News:New Data: Advanced Pharmacy Model Significantly Reduces Gaps in Care for Patients with Chronic and Complex Conditions; Improves Clinical and Financial Outcomes 5 Health News:New Data: Advanced Pharmacy Model Significantly Reduces Gaps in Care for Patients with Chronic and Complex Conditions; Improves Clinical and Financial Outcomes 6

[0] Heska to Present at New York Society of Security Analysts' 12th Annual Biotech and Specialty Pharma Conference [0] FDA Approves New Drug for Severe Epilepsy [0] NursingCenter.com Launches New Features to Improve User Experience [0] New Data: Advanced Pharmacy Model Significantly Reduces Gaps in Care for Patients with Chronic and Complex Conditions; Improves Clinical and Financial Outcomes

... and dental hygienists as lifesavers, but Dr. Gwen...ant professor of dental// hygiene at New York City...to routinely conduct periodontal evaluations and o...s well as how to recognize the clinical signs of s...

... cells from the lungs of transplant patients demon...ells //reside in adult organs and are not derived ...hat the cells may be able to help with the rejecti...kinds of lung disease. The study by University of...

...and the Medicines for Malaria Venture plan to fund...nited Arab Emirates (UAE). The center will focus o...Gulf News reports. Gates Foundation and MMV repre...ials from the UAE Ministry of Health to discuss th...

...e parents of Canada’s conjoined twins and to the p...have confirmed //after days of several tests that ...ined twins, known by the names Krista and Tatiana ...eads joined. The twins, who are four months of age...

Other Medicine News:Health News:Medical Personnel Can Save More Lives by Screening for Oral Signs of Disease 2 Health News:Medical Personnel Can Save More Lives by Screening for Oral Signs of Disease 3 Health News:Medical Personnel Can Save More Lives by Screening for Oral Signs of Disease 4 Health News:Stem Cell Finding Could Help Reduce Transplant Rejection 2 Health News:Stem Cell Finding Could Help Reduce Transplant Rejection 3

Medical Personnel Can Save More Lives by Screening for Oral Signs of Disease Stem Cell Finding Could Help Reduce Transplant Rejection Gates Foundation, MMV Plan To Fund Malaria Research Center in UAE Canada’s Conjoined Twins Growing Normall

(Date:11/13/2008)...ds Statins Cut Risk of Heart Attacks, Deaths, RES...ovascular Disease,is the leading cause of death am...eds of millions of dollars and causing untold suff...atal disease - even among those who,weren,t though...ions of people could cut their risk of a,heart att...

(Date:11/12/2008)...mes D. Watson, Marilyn & James Simons and,Sherry L...., Nov. 12 J. Craig Ven...Venter Institute (JCVI), was,awarded the Double He...) on,November 6th at a gala event in New York City...ng with Dr. James D.,Watson for making each of the...

(Date:11/12/2008)...Provides Reversible, High-level Platelet ...NEW ORLEANS and SOUTH SAN FRANCISCO, Calif., Nov. ...harmaceutical company developing innovative,drugs ...r and inflammatory,diseases, and cancer, today ann...8, the Company,s novel anti-platelet drug that dir...

(Date:11/12/2008)... its kind shows no clinically meaningful, differen... nearsightedness, JACKSONVILLE, Fla., Nov. 12 /PR...t in clinically significant acceleration in the de...not cause relevant increases in axial,length or co...the,three-year study, the largest randomized trial...

Breaking Medicine Technology:Seniors Can Be Heartened by New Study on Statins 2 J. Craig Venter, Ph.D. Receives Double Helix Medal from Cold Spring Harbor Laboratory 2 Portola Announces Data Showing Its Anti-Platelet Drug Inhibits Platelets in Clopidogrel (Plavix(R)) Non-Responders 2 Portola Announces Data Showing Its Anti-Platelet Drug Inhibits Platelets in Clopidogrel (Plavix(R)) Non-Responders 3 Soft Contact Lenses Do Not Lead to 'Myopic Creep' in Children, Study Shows 2 Soft Contact Lenses Do Not Lead to 'Myopic Creep' in Children, Study Shows 3 Chiltern Will Sponsor and Present at the 17th Annual Partnerships With CROs Meeting in Las Vegas April 14 16 2008 16386 1 Chiltern Will Sponsor and Present at the 17th Annual Partnerships With CROs Meeting in Las Vegas April 14 16 2008 16386 2 Obesity Costs U S Companies as Much as 2445 Billion a Year The Conference Board Reports 16384 1 Obesity Costs U S Companies as Much as 2445 Billion a Year The Conference Board Reports 16384 2 Obesity Costs U S Companies as Much as 2445 Billion a Year The Conference Board Reports 16384 3 MedPage Today 28R 29 Selects iSEEK 28TM 29 to Improve Quality of Patient Care 16382 1 MedPage Today 28R 29 Selects iSEEK 28TM 29 to Improve Quality of Patient Care 16382 2 MedPage Today 28R 29 Selects iSEEK 28TM 29 to Improve Quality of Patient Care 16382 3 MedPage Today 28R 29 Selects iSEEK 28TM 29 to Improve Quality of Patient Care 16382 4 ProMetic to obtain controlling stake in Pathogen Removal and Diagnostic Technologies Inc 4499 1 ProMetic to obtain controlling stake in Pathogen Removal and Diagnostic Technologies Inc 4499 2 ProMetic to obtain controlling stake in Pathogen Removal and Diagnostic Technologies Inc 4499 3 ProMetic to obtain controlling stake in Pathogen Removal and Diagnostic Technologies Inc 4499 4 ProMetic to obtain controlling stake in Pathogen Removal and Diagnostic Technologies Inc 4499 5 ProMetic to obtain controlling stake in Pathogen Removal and Diagnostic Technologies Inc 4499 6 ProMetic to obtain controlling stake in Pathogen Removal and Diagnostic Technologies Inc 4499 7

[1] Seniors Can Be Heartened by New Study on Statins [0] J. Craig Venter, Ph.D. Receives Double Helix Medal from Cold Spring Harbor Laboratory [0] Portola Announces Data Showing Its Anti-Platelet Drug Inhibits Platelets in Clopidogrel (Plavix(R)) Non-Responders [0] Soft Contact Lenses Do Not Lead to 'Myopic Creep' in Children, Study Shows

...s intramuscular injection of peramivir for eight,d...s infection and,inhibited virus replication, suppo...ring a pandemic, MEMPHIS, Tenn., May 01, 2007 /PRN...r might offer humans significant protection,during...ording to,results of mouse studies conducted by in...

...ND, Sweden--(BUSINESS WIRE)--May 1, 2007 - Teva,Ph... today,announced that data from a 36-week, randomi...udy demonstrated that an oral 0.6 mg,dose of laqui...esonance imaging (MRI) disease activity by 38 perc...dition, there was a favorable,trend towards reduci...

Other Medicine Technology:Peramivir Protects Mice From Lethal H5N1 Infection 2 Peramivir Protects Mice From Lethal H5N1 Infection 3 Laquinimod, a Novel Oral Compound, Showed Significant Reduction in,Disease Activity in Patients with Relapsing-Remitting Multiple,Sclerosis (RRMS) 2 Laquinimod, a Novel Oral Compound, Showed Significant Reduction in,Disease Activity in Patients with Relapsing-Remitting Multiple,Sclerosis (RRMS) 3 Laquinimod, a Novel Oral Compound, Showed Significant Reduction in,Disease Activity in Patients with Relapsing-Remitting Multiple,Sclerosis (RRMS) 4 Laquinimod, a Novel Oral Compound, Showed Significant Reduction in,Disease Activity in Patients with Relapsing-Remitting Multiple,Sclerosis (RRMS) 5 Laquinimod, a Novel Oral Compound, Showed Significant Reduction in,Disease Activity in Patients with Relapsing-Remitting Multiple,Sclerosis (RRMS) 6

Peramivir Protects Mice From Lethal H5N1 Infection Laquinimod, a Novel Oral Compound, Showed Significant Reduction in,Disease Activity in Patients with Relapsing-Remitting Multiple,Sclerosis (RRMS)